Armata Pharmaceuticals, Inc. (ARMP)
NYSE American · Healthcare · Biotechnology
$3.66+3.98%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $136M
- 52-week range
- $3.08 – $16.34
- 52-week change
- +10.00%
- EPS (trailing)
- −$5.29
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Net income
- −$174M
- Diluted EPS
- −$4.80
- Free cash flow
- −$26.3M
From the company’s annual report on SEC EDGAR.
About Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudomonas aeruginosa . The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.
Headquarters: Los Angeles, United States · 61 employees · armatapharma.com